Ibrutinib produces rapid and endurable respons... - CLL Support

CLL Support

23,257 members39,957 posts

Ibrutinib produces rapid and endurable responses. PFS and DOR not reached at up to 44 months -Steven Coutre's Lymphoma & Myeloma 2015 update

AussieNeil profile image
AussieNeilPartnerAdministrator
8 Replies

'Long-term follow-up of single-agent ibrutinib at the approved dose of 420 mg daily confirms that the Bruton’s tyrosine kinase inhibitor produces rapid and durable responses in patients with chronic lymphocytic leukemia (CLL), according to an update presented at Lymphoma & Myeloma 2015.

At up to 44 months of follow-up, the median duration of response (DOR) and progression-free survival (PFS) have not yet been reached.

At 30 months, the PFS rate was 96% for treatment-naïve patients and 76% for relapsed or refractory patients. Patients with del 17p had a median PFS of 32.4 months.

“Virtually all the patients do respond to treatment,” said Steven Coutre, MD, of Stanford University School of Medicine in California.'

Full article from Hematology Times (free registration)

hematologytimes.com/p_artic...

Neil

Written by
AussieNeil profile image
AussieNeil
Partner
To view profiles and participate in discussions please or .
Read more about...
8 Replies
Justasheet1 profile image
Justasheet1

Neil,

Great data.

Jeff

AussieNeil profile image
AussieNeilPartnerAdministrator

And in related news, if you've been on Ibrutinib for over a year and your lymphocyte count (ALC) remains high, it doesn't mean that you aren't doing well on Ibrutinib, it's just that you have a different flavour of CLL than other patients, or as this Blood Journal paper puts it:"Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy"

bloodjournal.org/content/12...

Thanks to member lapermone for bringing this article to my attention.

Neil

charliegirl profile image
charliegirl in reply toAussieNeil

Many thanks for posting this info, Neil

Excellent news for those of us who are on ibrutinib.

Charlie Girl

Jilltap profile image
Jilltap in reply toAussieNeil

Thank you. I am a slow responder and this info is helpful

manzelka profile image
manzelka

This is good to see as my husband is to start taking Ibrutinib tomorrow.

I am apprehensive about side effects.

nobby00 profile image
nobby00 in reply tomanzelka

my husband is due to start next ,very hopeful keep us informed

splashsplash3 profile image
splashsplash3

Thanks for this posting Neil, really good to hear that the good news continues past the four year point. Can we use the 'C' word yet - CURE?

I have only been on Ibrutinib on the NHS for six weeks after two previous relapses and two chemo courses of FCR.

After only two hours of taking the first Ibrutinib pill I began to feel a lot better and my Leukaemia cells started to drop virtually immediately and they continue to fall. So far I have no side effects even though after chemo I was expecting the worst.

Now after only a few weeks I have a 'normal' plus amount of energy and I can even cycle up hills and sprint up stairs.

Just a shame Ibrutinib is so expensive because it's the most amazing drug, quite magical.

tpetro profile image
tpetro

Do we have any sense when Ibrutinib will be available as frontline treatment in CLL?

Not what you're looking for?

You may also like...

From the CLL14 Study: Venetoclax Plus Obinutuzumab Prolongs Progression Free Survival, Not Overall Survival , in CLL

These results, from the CLL14 study (ClinicalTrials.gov Identifier: NCT02242942), were presented at...
Jm954 profile image
Administrator

Health Canada approves Ibrutinib plus Rituximab for First Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

Good News for our untreated Canadian members! This latest approval is based on...
AussieNeil profile image
Partner

FDA Approves Zanubrutinib for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphom

FDA Approves Zanubrutinib for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Jan 19,...
lankisterguy profile image
Volunteer

Response and Survival Rates for FCR and Ibrutinib

Those of you who waded through my post yesterday on clonal evolution will be glad to know this is a...
AdrianUK profile image

Adding Venetoclax to Obinutuzumab Prolongs Progression-Free Survival in Previously Untreated CLL

Dated 1st September 2019 In a phase III trial of patients with previously untreated CLL...
Jm954 profile image
Administrator